Hikma Pharmaceuticals PLC
H5P
Company Profile
Business description
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
Contact
1 New Burlington Place
LondonW1S 2HR
GBRT: +44 2073992760
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
9,603
Stocks News & Analysis
stocks
Fair value upgrade for this ASX income player
Headwinds in listed energy stocks likely to have passed
stocks
The SpaceX IPO and the Elon Musk factor
Potential investors should remember that the company’s controlling shareholder can move markets with a few words.
stocks
The ASX’s most shorted stocks in 2026
What we can and can’t learn from the top 20 most shorted ASX shares.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,668.20 | 4.20 | -0.05% |
| CAC 40 | 7,772.45 | 70.50 | 0.92% |
| DAX 40 | 22,562.88 | 262.13 | 1.18% |
| Dow JONES (US) | 45,216.14 | 49.50 | 0.11% |
| FTSE 100 | 10,127.96 | 160.61 | 1.61% |
| HKSE | 24,750.79 | 201.09 | -0.81% |
| NASDAQ | 20,794.64 | 153.72 | -0.73% |
| Nikkei 225 | 51,313.17 | 572.68 | -1.10% |
| NZX 50 Index | 12,768.62 | 19.70 | 0.15% |
| S&P 500 | 6,343.72 | 25.13 | -0.39% |
| S&P/ASX 200 | 8,473.40 | 3.80 | -0.04% |
| SSE Composite Index | 3,923.29 | 0.00 | 0.00% |